Share Name Share Symbol Market Type Share ISIN Share Description
Maxcyte Inc LSE:MXCT London Ordinary Share COM STK USD0.01 (DI)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.50p -1.26% 117.50p 115.00p 120.00p 119.00p 117.50p 119.00p 700 15:14:06
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 13.1 -7.0 -13.3 - 60

MaxCyte, Inc. Appointment of Joint Corporate Broker

12/06/2019 7:00am

UK Regulatory (RNS & others)

Maxcyte (LSE:MXCT)
Historical Stock Chart

6 Months : From Apr 2019 to Oct 2019

Click Here for more Maxcyte Charts.


RNS Number : 8822B

MaxCyte, Inc.

12 June 2019

MaxCyte, Inc.

("MaxCyte" or the "Company")

Appointment of Joint Corporate Broker

Gaithersburg, Maryland - 12 JUNE 2019: MaxCyte (LSE: MXCT, MXCS), the global clinical-stage, cell-based therapies and life sciences company, announces the appointment of Numis as the Company's joint Corporate Broker with immediate effect. Panmure Gordon will continue to act as the Company's Nominated Adviser and joint Corporate Broker.

About MaxCyte

MaxCyte is a global clinical-stage cell-based therapies and life sciences company applying its proprietary cell engineering platform to deliver the advances of cell-based therapy to patients with high unmet medical needs. MaxCyte is developing novel CARMA(TM) therapies for its own pipeline, with its first drug candidate in a Phase I clinical trial. CARMA is MaxCyte's mRNA-based proprietary therapeutic platform for autologous cell therapy for the treatment of solid cancers. In addition, through its life sciences business, MaxCyte leverages its Flow Electroporation(R) Technology to enable its biopharmaceutical partners to advance the development of innovative medicines, particularly in cell therapy. MaxCyte has placed its flow electroporation instruments worldwide, with all of the top ten global biopharmaceutical companies. The Company now has more than 70 partnered programme licenses in cell therapy with more than 35 licensed for clinical use, including four announced commercial licenses covering potentially more than 30 products with aggregate potential milestones of more than $250m plus significant additional potential milestones from the multi-drug commercial agreement with Kite announced 1 March 2019. With its robust delivery technology platform, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit

For further information, please contact:

 MaxCyte Inc. 
  Doug Doerfler, Chief Executive Officer 
  Ron Holtz, Chief Financial Officer                                +1 301 944 1660 
 Nominated Adviser and Joint Corporate 
  Panmure Gordon 
  Emma Earl 
  Freddy Crossley 
  Corporate Broking 
  James Stearns                                                      +44 (0)20 7886 2500 
 Joint Corporate Broker 
  Numis Securities Limited 
  James Black 
  Duncan Monteith                                                    +44 (0)20 7260 1000 
 Financial PR Adviser                                                +44 (0)203 709 5700 
  Consilium Strategic Communications                         
  Mary-Jane Elliott 
  Chris Welsh 
  Sukaina Virji 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit



(END) Dow Jones Newswires

June 12, 2019 02:00 ET (06:00 GMT)

1 Year Maxcyte Chart

1 Year Maxcyte Chart

1 Month Maxcyte Chart

1 Month Maxcyte Chart
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20191019 17:44:44